CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
N/A Nab-paclitaxel Gastrointestinal cancer Active
Qulipta atogepant Migraine, prevention Active
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active
Dificid fidaxomicin Clostridium difficile infection Active
TBC cabotegravir HIV-1 infection, pre-exposure prophylaxis Active
Velsipity etrasimod Ulcerative colitis Active
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Active
N/A nab-paclitaxel Gastrointestinal cancer Pending
Truqap capivasertib HR-positive, HER2-negative locally advanced or metastatic breast cancer Active
NA icatibant Hereditary Angioedema Active
Last Updated : May 10, 2024